DexCom slips as Abbott wins FDA nod for CGM integration
JHVEPhoto


DexCom (NASDAQ:DXCM) lost ~8% in the morning hours Monday after rival Abbott (ABT) announced the FDA clearance for its FreeStyle Libre 2 and FreeStyle Libre 3 continuous glucose monitoring (CGM) systems for integration with automated insulin delivery (AID) systems.
Concurrently, Abbott (ABT) also announced that it is working with insulin pump makers Insulet Corporation (PODD) and Tandem Diabetes Care (TNDM) to integrate their systems with FreeStyle Libre 2 and FreeStyle Libre 3 sensors "as soon as possible."

DexCom (DXCM) has already partnered with Insulet (PODD) and Tandem (TNDM), integrating its G6 CGMs for their insulin pumps. The company has already ramped up production in anticipation of the US rollout of its new G7 device.

During the recent earnings call, John Sheridan, chief executive of Tandem (TNDM), announced that its t: slim X2 insulin pump will be available with G7 integration in Q2 2023.

However, Insulet (PODD) refused to indicate a timeline, noting that efforts to integrate Omnipod 5 with DexCom's G7 and Abbott's Libre systems were already underway.